A Phase 2, Double-Blind, Placebo-Controlled, Randomized, International, Multicenter Study of Oral TAC 101 [amsilarotene] as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amsilarotene (Primary)
Indications Carcinoma; Liver cancer
Focus Therapeutic Use
Sponsors Taiho Pharmaceutical

Most Recent Events

05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database record.
03 Jul 2012 Additional trial locations added as reported by European Clinical Trials Database.
17 Mar 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight